[1] |
LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo.
Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
|
[2] |
GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai.
One case of multiple organ dysfunction syndrome caused by amlodipine overdose
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
|
[3] |
GAO Yuan, SHI Wei, XIAO Xiaohe, BAI Zhaofang, WANG Jiabo.
Research progress on the animal models of idiosyncratic drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 33-39.
|
[4] |
LI Shuran, GUO Shanshan, JI Zuen, ZHANG Wei, CUI Xiaolan.
Research status of cognitive dysfunction after SARS-CoV-2 infection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 59-64.
|
[5] |
LIU Min, CHEN Yan, LIU Wendong, WANG Haixue.
Updates and reflections on expedited reporting of safety information during drug clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
|
[6] |
XIA Xudong, LI Meixia, SUN Yang, YANG Shengya.
Processes of remote inspection of pharmacovigilance for marketing authorization holders
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
|
[7] |
LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing.
Management of individual adverse drug reaction reports
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
|
[8] |
PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu.
Exploring the significance of collecting patient reports based on international pharmacovigilance experience
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
|
[9] |
SHEN Yanjie, WU Yiqing.
Management of adverse events during clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
|
[10] |
LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue.
Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
|
[11] |
ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan.
Comparison standard terminology for pharmaceutical dose forms
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
|
[12] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[13] |
ZHAO Wenhua, SHU He, NI Chenming, GUO Jinmin.
Data mining and analysis of adverse drug reaction signals of fampridine sustained-release tablets based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 684-690.
|
[14] |
LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping.
Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
|
[15] |
HUO Peiqiong, ZHENG Peng, SU Zhenhao.
Pharmacovigilance in retail pharmacies for special or major diseases
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
|